Literature DB >> 10888613

Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1.

P Steigerwald-Mullen1, M G Kurilla, T J Braciale.   

Abstract

Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus that persistently infects 85% of the adult population worldwide. In this report, we examine the proliferative response and cytokine secretion profile of CD4(+) T lymphocytes from a panel of unrelated EBV-positive donors against two EBV latent antigens, EBNA1 and EBNA3C. Substantial proliferative responses by CD4(+) lymphocytes were demonstrated to both antigens in multiple, randomly selected donors. Surprisingly, we observed a striking and consistent difference in cytokine response to EBNA1 and EBNA3C. EBNA1-specific CD4(+) T lymphocytes from multiple unrelated donors preferentially produced type 2-like cytokines in response to antigenic stimulation, while the response to EBNA3C was a characteristic type 1 response. The implications of these findings for EBV persistence and the development of EBV-associated malignancies are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888613      PMCID: PMC112191          DOI: 10.1128/jvi.74.15.6748-6759.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Epstein-Barr virus latent infection in vivo.

Authors: 
Journal:  Rev Med Virol       Date:  1997-07       Impact factor: 6.989

Review 2.  Cytokines induce the development of functionally heterogeneous T helper cell subsets.

Authors:  A O'Garra
Journal:  Immunity       Date:  1998-03       Impact factor: 31.745

3.  Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.

Authors:  J Levitskaya; A Sharipo; A Leonchiks; A Ciechanover; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

Review 4.  Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches.

Authors:  S L Constant; K Bottomly
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

5.  CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection.

Authors:  T Hussell; C J Baldwin; A O'Garra; P J Openshaw
Journal:  Eur J Immunol       Date:  1997-12       Impact factor: 5.532

Review 6.  Acquisition of lymphokine-producing phenotype by CD4+ T cells.

Authors:  R A Seder; W E Paul
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

7.  Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: implications for long-term survival.

Authors:  E Barker; C E Mackewicz; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

Review 8.  Regulation of T cell subsets from naive to memory.

Authors:  L L Carter; X Zhang; C Dubey; P Rogers; L Tsui; S L Swain
Journal:  J Immunother       Date:  1998-05       Impact factor: 4.456

9.  Effects of IL-4, IL-5, and IL-6 on growth and immunoglobulin production of Epstein-Barr virus-infected human B cells.

Authors:  R J Bende; G J Jochems; T H Frame; M R Klein; R V van Eijk; R A van Lier; W P Zeijlemaker
Journal:  Cell Immunol       Date:  1992-09       Impact factor: 4.868

10.  Human T cell responses to the Epstein-Barr nuclear antigen-1 (EBNA-1) as evaluated by synthetic peptides.

Authors:  J Petersen; G Rhodes; K Patrick; J Roudier; J H Vaughan
Journal:  Cell Immunol       Date:  1989-10-15       Impact factor: 4.868

View more
  14 in total

1.  Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity.

Authors:  Nancy H Gudgeon; Graham S Taylor; Heather M Long; Tracey A Haigh; Alan B Rickinson
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

2.  CD4+ T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes.

Authors:  C W Tsang; X Lin; N H Gudgeon; G S Taylor; H Jia; E P Hui; A T C Chan; C K Lin; A B Rickinson
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

Review 3.  Epstein-Barr virus infection and human malignancies.

Authors:  G Niedobitek; N Meru; H J Delecluse
Journal:  Int J Exp Pathol       Date:  2001-06       Impact factor: 1.925

4.  Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.

Authors:  A Leen; P Meij; I Redchenko; J Middeldorp; E Bloemena; A Rickinson; N Blake
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  In vitro cytokine production and growth inhibition of lymphoblastoid cell lines by CD4+ T cells from Epstein-Barr virus (EBV) seropositive donors.

Authors:  A D Wilson; J C Hopkins; A J Morgan
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

6.  The Epstein-Barr Virus Major Tegument Protein BNRF1 Is a Common Target of Cytotoxic CD4+ T Cells.

Authors:  Josef Mautner; Uta Behrends; Dinesh Adhikary; Julia Damaschke
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

7.  Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo.

Authors:  Tihui Fu; Kui Shin Voo; Rong-Fu Wang
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

8.  Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines.

Authors:  Sumita Bhaduri-McIntosh; Marisa J Rotenberg; Benjamin Gardner; Marie Robert; George Miller
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

9.  Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  Sarah Nikiforow; Kim Bottomly; George Miller; Christian Münz
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines.

Authors:  H M Long; T A Haigh; N H Gudgeon; A M Leen; C-W Tsang; J Brooks; E Landais; E Houssaint; S P Lee; A B Rickinson; G S Taylor
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.